GRAIL
Menlo Park, US · 4 known investors
GRAIL develops the Galleri blood test for multi-cancer early detection using next-generation sequencing and machine learning to screen for multiple deadly cancer types before symptoms appear. The test is offered by prescription in the United States and through partnerships with healthcare systems, insurance carriers, and diagnostic platforms.
AI & Machine LearningBiotechHealthtechMedical Devices
Founders & leadership
JO
Joshua Ofman, MD, MSHSChief Executive Officer